MedTrace Logo

Ganoderma Spores Modulate the Gut-Brain Axis

NCT07524777 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-05-12

No results posted yet for this study

Summary

This study aims to investigate whether Sporoderm-removed Ganoderma lucidum spore powder (RGLS) ameliorates depression in thyroid cancer patients through gut-brain axis modulation, and to elucidate the underlying microbial and metabolic mechanisms. This 3-month randomized, double-blind, placebo-controlled trial will enroll 300 postoperative papillary thyroid carcinoma patients with depressive symptoms (HAMD-24 ≥ 8). Participants will be randomly assigned(2 : 1) to receive RGLS (4 g/day) or matched placebo.

Conditions

Interventions

DIETARY_SUPPLEMENT

Sporoderm-removed Ganoderma lucidum spore powder (RGLS)

From the first day after enrollment, subjects take RGLS orally at 4g/day for 3 months.

OTHER

Placebo

From the first day after enrollment, subjects take placebo orally at 4g/day for 3 months.

Sponsors & Collaborators

  • Ling Zhiqiang

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-11
Primary Completion
2026-07-31
Completion
2026-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07524777 on ClinicalTrials.gov